Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analysts Just Trimmed Their Revenue Forecasts By 19%
Analysts covering Recursion Pharmaceuticals (NASDAQ:RXRX) cut 2026 revenue forecasts by 19%, lowering consensus to about $53m, down 3.9% versus the prior 12 months. Loss per share is expected to improve slightly to about $0.88 versus $0.87 previously. The article also cites an expected annual revenue decline through 2026 versus prior growth.
How this was made
The 30-second read
Why it matters
A sharp revenue forecast reduction (about 19% per the headline) can drive estimate revisions, sentiment, and near-term positioning even without a corresponding EPS change.
Market read
Traders may reassess RXRX’s growth expectations versus peers after the forecast cut, despite stable EPS estimates.
What to watch
The article is based on analyst consensus revisions and does not cite new company-specific operational data, trial results, or guidance from Recursion.
Background
The piece summarizes a consensus downgrade for Recursion Pharmaceuticals, focusing on 2026 revenue and EPS expectations.
Ticker impact
Analysts cut Recursion Pharmaceuticals 2026 revenue forecasts to about $53m, down from $65m, signaling a weaker outlook.
Near-term downside bias as traders reprice growth expectations; magnitude depends on how RXRX’s valuation already reflects forecast risk.
The article provides specific forecast revisions (revenue down ~19%) and notes industry growth is expected to outpace RXRX, which typically pressures sentiment and forward estimates.
Market effects
Highlights heightened caution toward biotech/healthcare R&D revenue trajectories when analyst models shift toward slower growth.
No specific regional spillover described.
No direct global macro or cross-border catalyst mentioned.
Counterpoint
If EPS expectations are largely unchanged, the market may focus less on revenue and more on cost discipline or pipeline execution not captured by this revenue cut.
Key entities
- public_companyRecursion Pharmaceuticals, Inc.
Subject of the article, with analysts trimming 2026 revenue forecasts and leaving EPS largely unchanged.
